Olaparib for fallopian tube neoplasms

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 2 registered trials.

Why this status

  1. 6 Jul 2018: Trial registered, NCT03579316
  2. 7 Dec 2018: Trial started, NCT03579316
  3. 26 Sep 2022: Trial registered, NCT05554328
  4. 25 Apr 2023: Trial started, NCT05554328

The trials

NCT03579316: Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

State
Under way
Phase
Phase 2
People
96 taking part
Started
7 Dec 2018
Primary completion
31 Dec 2026
Arms
Arm II (olaparib, adavosertib)
Results
None posted
  1. 6 Jul 2018: Trial registered
  2. 7 Dec 2018: Trial started

NCT05554328: Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial

State
Under way
Phase
Phase 2
People
165 taking part
Started
25 Apr 2023
Primary completion
23 Sep 2026
Arms
Arm I (selumetinib, olaparib)
Results
None posted
  1. 26 Sep 2022: Trial registered
  2. 25 Apr 2023: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Also known as Lynparza.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.